share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股SEC公告 ·  2024/10/31 23:39

Moomoo AI 已提取核心訊息

On October 31, 2024, Conduit Pharmaceuticals, led by CEO David Tapolczay, requested the U.S. Securities and Exchange Commission (SEC) to expedite the effectiveness of its Registration Statement on Form S-3. The company aims for the statement to become effective on November 1, 2024, at 4:30 p.m. Eastern Time.This request is made under Rule 461 of the Securities Act of 1933. The company has appointed Todd Mason of Thompson Hine LLP as the contact for any inquiries related to this request. The effectiveness of the Registration Statement is crucial for Conduit Pharmaceuticals' strategic financial planning and potential capital raising activities.
On October 31, 2024, Conduit Pharmaceuticals, led by CEO David Tapolczay, requested the U.S. Securities and Exchange Commission (SEC) to expedite the effectiveness of its Registration Statement on Form S-3. The company aims for the statement to become effective on November 1, 2024, at 4:30 p.m. Eastern Time.This request is made under Rule 461 of the Securities Act of 1933. The company has appointed Todd Mason of Thompson Hine LLP as the contact for any inquiries related to this request. The effectiveness of the Registration Statement is crucial for Conduit Pharmaceuticals' strategic financial planning and potential capital raising activities.
2024年10月31日,由首席執行官戴維·塔波爾扎伊領導的Conduit Pharmicalsumicals要求美國證券交易委員會(SEC)加快其S-3表格註冊聲明的生效。該公司的目標是該聲明於美國東部時間2024年11月1日下午 4:30 生效。該請求是根據1933年《證券法》第461條提出的。該公司已任命湯普森·海因律師事務所的託德·梅森爲與該請求有關的任何查詢的聯繫人。註冊聲明的有效性對於Conduit Pharmaceuticals的戰略財務規劃和潛在的籌資活動至關重要。
2024年10月31日,由首席執行官戴維·塔波爾扎伊領導的Conduit Pharmicalsumicals要求美國證券交易委員會(SEC)加快其S-3表格註冊聲明的生效。該公司的目標是該聲明於美國東部時間2024年11月1日下午 4:30 生效。該請求是根據1933年《證券法》第461條提出的。該公司已任命湯普森·海因律師事務所的託德·梅森爲與該請求有關的任何查詢的聯繫人。註冊聲明的有效性對於Conduit Pharmaceuticals的戰略財務規劃和潛在的籌資活動至關重要。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息